Abstract
The Omicron SARS-CoV-2 variant has become the dominant lineage worldwide, and experimental study had shown that SARS-CoV-2 Omicron variant was more stable on various environmental surfaces than ancestral strain. However, how the changes of stability on surfaces would influence the role of fomite route in SARS-CoV-2 transmission is still unknown. In this study, we modeled the Omicron and ancestral strain SARS-CoV-2 transmission within a household over 1-day period from multiple pathways, i.e., airborne, droplet and contact route. We assumed there were 2 adults and 1 child in the household, and one of the adults was infected with SARS-CoV-2. We assume a scenario of pre-/asymptomatic infection, i.e., SARS-CoV-2 was emitted by breathing and talking, and symptomatic infection, i.e., SARS-CoV-2 was emitted by breathing, talking, and coughing. In pre-/asymptomatic infection, all three routes contributed a role, contact route contribute most (37%-45%), followed by airborne route (34%-38%) and droplet route (21%-28%). In symptomatic infection, droplet route was the dominant pathway (48%-71%), followed by contact route (25%-42%), airborne route played a negligible role (<10%). In the contact route, indirect contact (fomite) route dominated (contributed more than 97%). Compared with ancestral strain, though the contribution of contact route increased in Omicron variant transmission, the increase was slight, from 25%-41% to 30%-45%.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Our study do not use human data.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
